Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...

Arcus Capital Partners LLC grew its holdings in shares of JPMorgan Chase & Co. (NYSE:JPM) by 31.7% during the fourth quarter, ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Arcus Capital Partners LLC boosted its position in Meta Platforms, Inc. (NASDAQ:META – Free Report) by 6.9% during the fourth ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Tivozanib at 1.34 mg showed greater antitumor activity than 0.89 mg, with similar hypertension rates, in kidney cancer.

Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen ...